MedPath

Invasive intervention study of the safety of fibrinogen concentrate used in obstetric hemorrhage

Not Applicable
Conditions
Obstetric hemorrhage
Registration Number
JPRN-jRCTs031180414
Lead Sponsor
Iwase Akira
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
25
Inclusion Criteria

1) Patient during pregnancy or postpartum
2) Patient who meet any of the following 1-4
1. SI value> 1.0 or vaginal delivery when the amount of bleeding> 1000ml (cesarean section when the amount of bleeding> 2000ml), patients which is more persistent bleeding is found
2. SI value> 1.5 are observed frequently.
3. Obstetric DIC score more than 8 points
4. Objective symptoms suggestive of circulatory failure such as oliguria, peripheral cold sweat and SpO2 decrease.
3)Inpatient and outpatient
4)Patient consent with respect to participation in this study has been obtained in writing

Exclusion Criteria

Patient who are judged to be inappropriate as a target by the discretion of physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of transfusion-associated circulatory overload(TACO) due to the large amount of blood transfusion for less than one week after the intervention start
Secondary Outcome Measures
NameTimeMethod
We compare the fibrinogen values before and after administration of the test drug and analyze how many fibrinogen increase action per 1g of the test drug. We obtain the average value of the numerical value for each patient and take as the expected value of the fibrinogen increasing action by the test drug.
© Copyright 2025. All Rights Reserved by MedPath